Six decades after lithium became psychiatry's gold standard for bipolar disorder, a critical knowledge gap persists in managing its potentially dangerous side effects. While two-thirds of patients achieve meaningful symptom improvement, the medication's narrow margin between therapeutic benefit and toxicity continues to challenge clinicians worldwide. The comprehensive analysis examines three distinct toxicity patterns—acute poisoning, chronic accumulation, and acute episodes in long-term users—each presenting unique diagnostic and treatment challenges. Key findings highlight how common medications including NSAIDs, diuretics, and ACE inhibitors can precipitate dangerous lithium accumulation, while age-related kidney changes compound toxicity risks in older patients. The research reveals that lithium's effects span multiple organ systems, with renal damage, neurological complications, cardiovascular disruptions, and endocrine dysfunction representing the most concerning adverse events. Beyond bipolar management, emerging applications for neurodegenerative conditions are expanding lithium's clinical footprint despite these safety concerns. This review arrives at a crucial moment as precision medicine approaches seek to optimize lithium therapy through improved monitoring protocols and personalized dosing strategies. The emphasis on gradual discontinuation protocols reflects growing recognition that abrupt lithium cessation can trigger severe rebound episodes. For clinicians managing lithium therapy, this synthesis provides essential risk stratification tools and monitoring frameworks. However, the persistent challenge of balancing therapeutic efficacy against potentially serious adverse effects underscores the urgent need for safer mood stabilizing alternatives or enhanced predictive tools for identifying high-risk patients before toxicity develops.